Online inquiry

IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1469MR)

This product GTTS-WQ1469MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1469MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7698MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ5923MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ4893MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ2932MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ6897MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ14092MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ6233MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ994MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW